{"entity":{"id":"ksq-001ex","kind":"drug","name":"KSQ-001EX","aka":[],"tldr":"KSQ-001EX is an experimental engineered immune-cell therapy from KSQ Therapeutics, in phase 1 trials for melanoma, lung cancer and head and neck cancer.","summary":"KSQ-001EX is an autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy from KSQ Therapeutics. Tumour-infiltrating lymphocytes with the SOCS1 gene switched off by CRISPR/Cas9, which the company says improves their anti-tumour activity, engraftment and persistence. Its phase 1/2 study (NCT06237881) is active but not recruiting; the company presented first-in-human phase 1 results at AACR in April 2026. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"KSQ Therapeutics pipeline","url":"https://ksqtx.com/pipeline/"},{"label":"ClinicalTrials.gov NCT06237881","url":"https://clinicaltrials.gov/study/NCT06237881"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck"],"sections":[],"technologies":[],"targets":["socs1"],"drugs":[],"companies":["ksq-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06237881"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"KSQ-001EX","modality":"Autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy","mechanism":"Tumour-infiltrating lymphocytes with the SOCS1 gene switched off by CRISPR/Cas9, which the company says improves their anti-tumour activity, engraftment and persistence.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ksq-001ex/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/"}],"company":[{"id":"ksq-therapeutics","kind":"company","name":"KSQ Therapeutics","route":"/companies/ksq-therapeutics/"}],"trial":[{"id":"nct06237881","kind":"trial","name":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","route":"/trials/nct06237881/"}]}}